Evotec (EVO) issued the following comment on the withdrawn non-binding offer: “Evotec SE has taken notice of the statement made by Halozyme (HALO) Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE for EUR11.00 per share in cash. The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec. The Management Board and Supervisory Board continue to have strong conviction in the Company’s standalone strategy, which is expected to accelerate growth, strengthen the long-term profitability of the Company and deliver significant value to shareholders.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVO:
- Evotec falls 21% to $4.20 after Halozyme withdraws acquisition proposal
- Halozyme withdraws proposal to acquire Evotec
- Halozyme withdraws proposal to acquire Evotec for EUR 11.00 per share in cash
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Halozyme provides update on proposal to combine with Evotec
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
